LBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
LB PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$38.81+2.07 (+5.63%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$23.21 (+148.8%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.17B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.52
- Dividend yield
- –
- Free cash flow yield
- -7.08%
Fundamentals
- Net income
- -$85.69M
- EPS, diluted
- -$3.13
- Free cash flow
- -$82.83M
- Book value per share
- $11.03
- Diluted shares
- 30M
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Net income
-$85.69M
EPS, diluted
–
Free cash flow
-$82.83M
Reported periodTrailing twelve months